financetom
Business
financetom
/
Business
/
Alight's $1.2 Billion Business Sale Likely to Drive Stronger Gross Margins, Higher Recurring Revenue Over Mid-Term, Wedbush Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Alight's $1.2 Billion Business Sale Likely to Drive Stronger Gross Margins, Higher Recurring Revenue Over Mid-Term, Wedbush Says
Aug 8, 2024 9:49 AM

12:27 PM EDT, 08/08/2024 (MT Newswires) -- Alight's (ALIT) closing of the $1.2 billion sale of its payroll and professional services business negatively impacted its Q2 revenue but is expected to drive stronger gross margins and higher recurring revenue, over the mid-term, Wedbush said in a note to clients Thursday.

The company's total revenue in Q2 fell 4% year-over-year to $538 million due to decreased volumes and project revenue impacts, while non-GAAP earnings stood at $0.05 per share, missing the $0.11 estimate, Wedbush said.

Alight said Tuesday its adjusted earnings before interest, taxes, depreciation and amortization in Q2 was $105 million, down from $119 million a year earlier.

"While the transaction is a headwind to revenues, it will provide [Alight] stronger [earnings before interest, taxes, depreciation and amortization] and gross margins along with higher recurring revenues over the mid-term to help meet the board's goals for strategic portfolio review and further accelerate margin expansion and more recurring revenue," Wedbush said.

Alight also recently announced that Chief Executive Stephan Scholl will step down once a successor is found. Scholl will stay on during the search, with independent Director Dave Guilmette appointed as vice chair to facilitate a smooth transition.

For H2, Alight expects revenue of $1.21 billion to $1.23 billion, boosted by Business Process as a Service revenue, according to the note.

"Overall, while it is very disappointing to see Stephan leave and a disappointing quarter, we believe [Alight] is well-positioned longer term following its divesture of its payroll and professional services business with higher-value [Business Process as a Service] deals the focus," Wedbush said.

Wedbush maintained an outperform rating on Alight but lowered its price target to $10 from $12.

Price: 6.86, Change: +0.07, Percent Change: +0.96

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved